The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach

[1]  G. Petsko,et al.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations , 2015, The Lancet Neurology.

[2]  E. Masliah,et al.  Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy , 2015, Molecular Neurodegeneration.

[3]  S. Gilman,et al.  Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial , 2015, The Lancet Neurology.

[4]  E. Bézard,et al.  Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies , 2014, Neurobiology of Disease.

[5]  K. Bötzel,et al.  The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset , 2014, Acta Neuropathologica.

[6]  S. Gilman,et al.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.

[7]  S. Prusiner,et al.  Transmission of multiple system atrophy prions to transgenic mice , 2013, Proceedings of the National Academy of Sciences.

[8]  J. Kelly,et al.  Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. , 2013, Journal of the American Chemical Society.

[9]  P. Tavan,et al.  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease , 2013, Acta Neuropathologica.

[10]  Günther Deuschl,et al.  The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.

[11]  G. Wenning,et al.  Multiple system atrophy. , 2013, Handbook of clinical neurology.

[12]  E. Wanker,et al.  Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? , 2013, EPMA Journal.

[13]  E M Haacke,et al.  Different Iron-Deposition Patterns of Multiple System Atrophy with Predominant Parkinsonism and Idiopathetic Parkinson Diseases Demonstrated by Phase-Corrected Susceptibility-Weighted Imaging , 2012, American Journal of Neuroradiology.

[14]  A. Giese,et al.  Inhibition and disaggregation of α‐synuclein oligomers by natural polyphenolic compounds , 2011, FEBS letters.

[15]  E. Masliah,et al.  Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors , 2010, The Journal of Neuroscience.

[16]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[17]  Stefan Klöppel,et al.  Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures , 2010, NeuroImage.

[18]  Alexander Gerhard,et al.  Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) , 2010, Movement disorders : official journal of the Movement Disorder Society.

[19]  L. Astrakas,et al.  Voxel‐Based Morphometry and Voxel‐Based Relaxometry in Parkinsonian Variant of Multiple System Atrophy , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[20]  C. Richter-Landsberg,et al.  α-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells* , 2009, Journal of Biological Chemistry.

[21]  G. Mazzanti,et al.  Hepatotoxicity from green tea: a review of the literature and two unpublished cases , 2009, European Journal of Clinical Pharmacology.

[22]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[23]  M. Vidailhet,et al.  Risk factors of multiple system atrophy: A case‐control study in French patients , 2008, Movement disorders : official journal of the Movement Disorder Society.

[24]  Gang Hu,et al.  Coffee and tea consumption and the risk of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[25]  Karsten Specht,et al.  Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy—A comparison between clinical subtypes and correlations with clinical parameters , 2007, NeuroImage.

[26]  T. Tsai,et al.  Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. , 2007, Journal of agricultural and food chemistry.

[27]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[28]  J. Girault,et al.  Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. , 2004, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[29]  M. Youdim,et al.  Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.

[30]  Yi Zhao,et al.  Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese , 2003, Journal of the Neurological Sciences.

[31]  Harvey Checkoway,et al.  Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. , 2002, American journal of epidemiology.

[32]  S. Mandel,et al.  Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration , 2001, Journal of neurochemistry.